Family · Pharmaceutical analytical standards
Xanomeline
A muscarinic M1 and M4 receptor agonist studied in the 1990s for Alzheimer's disease; in 2024 it was approved in the United States for schizophrenia, in combination with trospium. This family brings together the active ingredient, metabolites, labelled standards and other impurities.
Did you know?It is the first antipsychotic that acts on cholinergic receptors instead of dopamine receptors; trospium, which does not cross the blood-brain barrier, curbs its effects on the rest of the body.
No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.
